ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Predicting hyperprogressive disease in patients with advanced hepatocellular carcinoma treated with anti-programmed cell death 1 therapy

Zhang, Lu*; Wu, Lingeng; Chen, Qiuying; Zhang, Bin; Liu, Jing; Liu, Shuyi; Mo, Xiaokai; Li, Minmin; Chen, Zhuozhi; Chen, Luyan; You, Jingjing; Jin, Zhe; Chen, Xudong*; Zhou, Zejian*; Zhang, Shuixing*广东省人民医院; 汕头大学; 1
ECLINICALMEDICINE2021-1DOI: 10.1016/j.eclinm.2020.100673
23被引7阅读
引用收藏
分享

摘要

Background: Hyperprogressive disease (HPD) is a new progressive pattern in patients with advanced hepatocellular carcinoma (HCC) treated with programmed cell death 1 (PD-1) inhibitors. We aimed to investigate risk factors associated with HPD in advanced HCC patients undergoing anti-PD-1 therapy. @@@ Methods: A total of 69 patients treated with anti-PD-1 therapy between March 2017 and January 2020 were included. HPD was determined according to the time to treatment failure, tumour growth rate, and tumour growth rate ratio. Univariate and multivariate analyses were performed to identify clinical variables significantly associated with HPD. A risk model was constructed based on clinical variables with prognostic significance for HPD. @@@ Findings: Overall, 10 (14.49%) had HPD. Haemoglobin level, portal vein tumour thrombus, and Child-Pugh score were significantly associated with HPD. The risk model had an area under the curve of 0.931 (95% confidence interval, 0.844-1.000). Patients with HPD had a significantly shorter overall survival (OS) than that of the patients with non-HPD (p < 0.001). However, there was no significant difference in OS between PD (progressive disease) patients with and without HPD (p = 0.05). @@@ Interpretation: We identified three clinical variables as risk factors for HPD, providing an opportunity to aid the pre-treatment evaluation of the risk of HPD in patients treated with immunotherapy.

学科与关键词

关键词
Hyperprogressive diseaseProgrammed cell death 1Immune checkpoint inhibitorsHepatocellular carcinoma
相关
加载中…
  • Lung metastasis and lymph node metastasis are risk factors for hyperprogressive disease in primary liver cancer patients treated with immune checkpoint inhibitors
    Xiao, Lu-Shan; Li, Qi-Mei; Hu, Cheng-Yi; Cui, Hao; Hong, Chang; Huang, Chao-Yi; Li, Rui-Ning; Dong, Zhong-Yi; Zhu, Hong-Bo; Liu, Li*Annals of Palliative Medicine, 2021, 10(11): 11244-+.被引 7
  • Hyperprogressive Disease Caused by PD-1 Inhibitors for the Treatment of Pan-Cancer
    Chen, Shiyun; Gou, Miaomiao; Yan, Huan; Fan, Mengjiao; Pan, Yuting; Fan, Runjia; Qian, Niansong*; Dai, Guanghai*DISEASE MARKERS, 2021, 2021: 6639366.被引 13
  • Efficiency and safety of hepatic arterial infusion chemotherapy (HAIC) combined with anti-PD1 therapy versus HAIC monotherapy for advanced hepatocellular carcinoma: A multicenter propensity score matching analysis
    Li, Yangyang; Liu, Wendao; Chen, Junwei; Chen, Yongxin; Guo, Jiandong; Pang, Huajin; Zhang, Wentao; An, Chao*; Li, Chengzhi*Cancer Medicine, 2024, 13(1).
查看全部 →

发表信息

论文状态
公开发表
期刊
ECLINICALMEDICINE
发表日期
2021-01
卷期
第 31 卷
页码
100673
DOI
10.1016/j.eclinm.2020.100673
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81571664,81871323, 81801665]; National Natural Science Foundation of Guangdong Province [2018B030311024]; Scientific Research General Project of Guangzhou Science Technology and Innovation Commission [20107010328]; China Postdoctoral Science Foundation [2016M600145]

作者

  • Z

    Zhang, Lu (通讯) (第一作者)

    1

  • W

    Wu, Lingeng

    guangdong prov peoples hosp · shantou univ

查看全部 15 位作者收起作者
  • C

    Chen, Qiuying

    1

  • Z

    Zhang, Bin

    1

  • L

    Liu, Jing

    1

  • L

    Liu, Shuyi

    1

  • M

    Mo, Xiaokai

    1

  • L

    Li, Minmin

    1

  • C

    Chen, Zhuozhi

    1

  • C

    Chen, Luyan

    1

  • Y

    You, Jingjing

    1

  • J

    Jin, Zhe

    1

  • C

    Chen, Xudong (通讯)

    1

  • Z

    Zhou, Zejian (通讯)

    guangdong prov peoples hosp

  • Z

    Zhang, Shuixing (通讯)

    1

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417